|
Gene: LCLAT1 |
Gene summary for LCLAT1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | LCLAT1 | Gene ID | 253558 |
Gene name | lysocardiolipin acyltransferase 1 | |
Gene Alias | 1AGPAT8 | |
Cytomap | 2p23.1 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q6UWP7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
253558 | LCLAT1 | CCI_1 | Human | Cervix | CC | 1.49e-06 | 6.24e-01 | 0.528 |
253558 | LCLAT1 | CCI_2 | Human | Cervix | CC | 2.40e-07 | 7.44e-01 | 0.5249 |
253558 | LCLAT1 | CCI_3 | Human | Cervix | CC | 4.17e-04 | 4.59e-01 | 0.516 |
253558 | LCLAT1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.63e-09 | -4.80e-01 | 0.0155 |
253558 | LCLAT1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.41e-03 | -5.06e-01 | -0.1207 |
253558 | LCLAT1 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.53e-08 | -4.54e-01 | -0.1464 |
253558 | LCLAT1 | HTA11_866_2000001011 | Human | Colorectum | AD | 4.04e-09 | -4.74e-01 | -0.1001 |
253558 | LCLAT1 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.68e-11 | -5.57e-01 | 0.096 |
253558 | LCLAT1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.49e-03 | -4.79e-01 | 0.0338 |
253558 | LCLAT1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.61e-15 | -5.61e-01 | 0.0674 |
253558 | LCLAT1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.56e-02 | -4.19e-01 | 0.0588 |
253558 | LCLAT1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.99e-02 | -3.39e-01 | 0.3859 |
253558 | LCLAT1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 4.92e-07 | -6.83e-01 | 0.2585 |
253558 | LCLAT1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.29e-12 | -5.19e-01 | 0.3005 |
253558 | LCLAT1 | F007 | Human | Colorectum | FAP | 3.95e-07 | -5.42e-01 | 0.1176 |
253558 | LCLAT1 | A001-C-207 | Human | Colorectum | FAP | 5.31e-04 | -3.34e-01 | 0.1278 |
253558 | LCLAT1 | A015-C-203 | Human | Colorectum | FAP | 4.11e-27 | -5.94e-01 | -0.1294 |
253558 | LCLAT1 | A015-C-204 | Human | Colorectum | FAP | 1.16e-07 | -3.66e-01 | -0.0228 |
253558 | LCLAT1 | A014-C-040 | Human | Colorectum | FAP | 2.44e-02 | -3.36e-01 | -0.1184 |
253558 | LCLAT1 | A002-C-201 | Human | Colorectum | FAP | 2.04e-16 | -4.95e-01 | 0.0324 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006650 | Colorectum | AD | glycerophospholipid metabolic process | 83/3918 | 306/18723 | 5.40e-03 | 3.55e-02 | 83 |
GO:0006644 | Colorectum | AD | phospholipid metabolic process | 101/3918 | 383/18723 | 5.80e-03 | 3.67e-02 | 101 |
GO:0045017 | Colorectum | AD | glycerolipid biosynthetic process | 69/3918 | 252/18723 | 8.33e-03 | 4.88e-02 | 69 |
GO:0008654 | Colorectum | FAP | phospholipid biosynthetic process | 54/2622 | 253/18723 | 8.88e-04 | 9.08e-03 | 54 |
GO:00066502 | Colorectum | FAP | glycerophospholipid metabolic process | 62/2622 | 306/18723 | 1.54e-03 | 1.38e-02 | 62 |
GO:00066442 | Colorectum | FAP | phospholipid metabolic process | 74/2622 | 383/18723 | 2.24e-03 | 1.83e-02 | 74 |
GO:0046473 | Colorectum | FAP | phosphatidic acid metabolic process | 12/2622 | 37/18723 | 3.43e-03 | 2.48e-02 | 12 |
GO:0046474 | Colorectum | FAP | glycerophospholipid biosynthetic process | 44/2622 | 211/18723 | 3.98e-03 | 2.76e-02 | 44 |
GO:00450172 | Colorectum | FAP | glycerolipid biosynthetic process | 50/2622 | 252/18723 | 6.32e-03 | 3.95e-02 | 50 |
GO:00086541 | Colorectum | CRC | phospholipid biosynthetic process | 49/2078 | 253/18723 | 7.07e-05 | 1.51e-03 | 49 |
GO:00066503 | Colorectum | CRC | glycerophospholipid metabolic process | 55/2078 | 306/18723 | 2.10e-04 | 3.55e-03 | 55 |
GO:00450173 | Colorectum | CRC | glycerolipid biosynthetic process | 47/2078 | 252/18723 | 2.47e-04 | 4.06e-03 | 47 |
GO:00066443 | Colorectum | CRC | phospholipid metabolic process | 65/2078 | 383/18723 | 3.21e-04 | 4.95e-03 | 65 |
GO:00464741 | Colorectum | CRC | glycerophospholipid biosynthetic process | 40/2078 | 211/18723 | 4.91e-04 | 7.02e-03 | 40 |
GO:00464861 | Colorectum | CRC | glycerolipid metabolic process | 64/2078 | 392/18723 | 1.01e-03 | 1.19e-02 | 64 |
GO:00464731 | Colorectum | CRC | phosphatidic acid metabolic process | 10/2078 | 37/18723 | 5.78e-03 | 4.31e-02 | 10 |
GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa00561 | Colorectum | AD | Glycerolipid metabolism | 24/2092 | 63/8465 | 1.25e-02 | 4.54e-02 | 2.90e-02 | 24 |
hsa005611 | Colorectum | AD | Glycerolipid metabolism | 24/2092 | 63/8465 | 1.25e-02 | 4.54e-02 | 2.90e-02 | 24 |
hsa005612 | Colorectum | MSS | Glycerolipid metabolism | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
hsa005613 | Colorectum | MSS | Glycerolipid metabolism | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
hsa005615 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
hsa0056112 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LCLAT1 | SNV | Missense_Mutation | rs780206248 | c.547G>A | p.Glu183Lys | p.E183K | Q6UWP7 | protein_coding | tolerated(0.18) | benign(0.106) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LCLAT1 | SNV | Missense_Mutation | rs769660456 | c.778N>T | p.Ala260Ser | p.A260S | Q6UWP7 | protein_coding | deleterious(0.01) | possibly_damaging(0.889) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
LCLAT1 | SNV | Missense_Mutation | rs374373733 | c.946N>T | p.Arg316Cys | p.R316C | Q6UWP7 | protein_coding | deleterious(0.01) | benign(0.007) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LCLAT1 | SNV | Missense_Mutation | c.208N>T | p.Met70Leu | p.M70L | Q6UWP7 | protein_coding | tolerated(0.22) | benign(0.031) | TCGA-AG-3591-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unspecific | Complete Response | ||
LCLAT1 | SNV | Missense_Mutation | rs750655578 | c.452N>T | p.Ala151Val | p.A151V | Q6UWP7 | protein_coding | deleterious(0.04) | benign(0.196) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LCLAT1 | SNV | Missense_Mutation | novel | c.877C>A | p.Leu293Ile | p.L293I | Q6UWP7 | protein_coding | tolerated(0.22) | benign(0.122) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LCLAT1 | SNV | Missense_Mutation | rs745720629 | c.1135N>A | p.Val379Ile | p.V379I | Q6UWP7 | protein_coding | tolerated(0.42) | benign(0) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
LCLAT1 | SNV | Missense_Mutation | novel | c.833N>T | p.Pro278Leu | p.P278L | Q6UWP7 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AP-A05O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
LCLAT1 | SNV | Missense_Mutation | c.154N>C | p.Phe52Leu | p.F52L | Q6UWP7 | protein_coding | tolerated(0.07) | benign(0.018) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
LCLAT1 | SNV | Missense_Mutation | c.701N>T | p.Arg234Ile | p.R234I | Q6UWP7 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |